4.7 Article

Bovine colostrum as a fortifier to human milk in very preterm infants-A randomized controlled trial (FortiColos)

期刊

CLINICAL NUTRITION
卷 42, 期 5, 页码 773-783

出版社

CHURCHILL LIVINGSTONE
DOI: 10.1016/j.clnu.2023.03.008

关键词

Prematurity; Growth; Human milk; Fortification; Amino acid metabolism

向作者/读者索取更多资源

Investigating the use of intact bovine colostrum as a fortifier for human milk in very preterm infants, it was found that it is feasible, safe, and showed preliminary efficacy in terms of growth and blood biochemistry. The fortification with bovine colostrum resulted in similar growth but provided more protein and elevated amino acid levels compared to conventional fortifiers.
Background: Human milk for very preterm infants need fortification for optimal growth and develop-ment but the optimal fortification product remains to be identified. Aims: To investigate feasibility, safety and preliminary efficacy on growth and blood biochemistry when using intact bovine colostrum (BC) as a fortifier to human milk in very preterm infants. Methods: In an open-label, multicenter, randomized controlled pilot trial (infants 26-31 weeks' = gesta-tion), mother's own milk or donor human milk was fortified with powdered BC (n 115) or a con-ventional fortifier (CF, bovine-milk-based, n = 117) until 35 weeks' postmenstrual age. Fortifiers and additional micronutrients were added to human milk according to local guidelines to achieve optimal growth (additional protein up to +1.4 g protein/100 mL human milk). Anthropometry was recorded weekly. Clinical morbidities including necrotizing enterocolitis (NEC) and late-onset sepsis (LOS) were recorded. Clinical biochemistry included plasma amino acid (AA) levels to assess protein metabolic re-sponses to the new fortifier. Results: A total of 232 infants, gestational age (GA) 28.5 +/- 1.4 (weeks + days), fulfilled inclusion criteria. Birthweight, GA and delta Z scores from birth to end of intervention on weight, length or head circumference did not differ between groups, nor between the subgroups of small for gestational age infants. Likewise, incidence of NEC (BC: 3/115 vs. CF: 5/117, p = 0.72, unadjusted values), LOS (BC: 23/113 vs. CF: 14/116, p = 0.08) and other morbidities did not differ. BC infants received more protein than CF infants (+10%, p < 0.05) and showed several elevated AA levels (+10-40%, p < 0.05). Conclusion: Infants fortified with BC showed similar growth but received more protein and showed a moderate increase in plasma AA-levels, compared with CF. Adjustments in protein composition and micronutrients in BC-based fortifiers may be required to fully suit the needs for very preterm infants. (c) 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据